Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation

Conclusion:
Sorafenib improves survival and is superior to the BSC in cases of untreatable posttransplant hepatocellular carcinoma recurrence.

Source: Progress in Transplantation - November 20, 2016 Category: Transplant Surgery Authors: deAngelis, N., Landi, F., Nencioni, M., Palen, A., Lahat, E., Salloum, C., Compagnon, P., Lim, C., Costentin, C., Calderaro, J., Luciani, A., Feray, C., Azoulay, D. Tags: Research Source Type: research